AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
STD quarterly
Immunization schedule may soon grow, HPV vaccine under regulatory review
Quadrivalent vaccine up for evaluation, bivalent vaccine to follow
(Editor's note: This article discusses pharmaceuticals not approved by the Food and Drug Administration.)
As you perform physical exams for your college-bound patients, you tick off the number of vaccinations needed to bring their immunizations up to schedule. You may soon be adding another shot. At press time, the Food and Drug Administration (FDA) was scheduled to take action on a vaccination that protects against cervical cancer.
The regulatory agency was scheduled to take action on Gardasil, developed by Merck & Co. in Whitehouse Station, NJ, by June 8, following an advisory panel's May 18 recommendation of the vaccination. If approved, it will be the first such vaccine on the market.
Clinical trials on Gardasil are ongoing, but primary data have been submitted to the FDA, reports Kelley Dougherty, Merck spokeswoman. The company submitted data in December 2005, and it was…
Source: HighBeam Research, STD Quarterly: Immunization schedule may soon grow, HPV vaccine under...